secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0001157523-22-000494
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q1 product revenue $187M, GAAP loss $240M; lowers 2022 guidance to $870-930M
--------------------------------------------------------------------------------

- Q1 total net product revenue $187M (+38% YoY); GAAP net loss $240M ($2.00 EPS), non-GAAP loss $180M ($1.49 EPS).
- Lowered 2022 combined revenue guidance to $870-930M from $900M-$1B due to Q1 pandemic impact and non-recurring Q4 2021 benefits.
- FDA extended vutrisiran NDA review to July 14, 2022; company expects launch upon approval if cleared.
- Patient growth: ONPATTRO >2,200 (+7%), GIVLAARI >400 (+14%), OXLUMO >160 (+14%) QoQ.
- Initiated Phase 1 for ALN-APP (Alzheimer's) and ALN-XDH (gout); filed patent suits against Pfizer/Moderna for COVID-19 vaccine lipids.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000115752322000494/0001157523-22-000494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000115752322000494/a52699629.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer